Last updated: 2026-09-16 10:32:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
IN8bio, Inc. (INAB) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.05, with a market capitalisation of $10.94M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.88 to $2.73. This page covers its latest market performance, valuation, price trends and company information.
$10.94M | |
$1.05 | |
$309.57 | |
$0.88 | |
$1.05 | |
636.00 | |
55.04K | |
-- | |
$2.73 | |
$0.88 | |
-- | |
-- |
IN8bio, Inc. (INAB) is trading at $1.05 in pre-market trading as of 2026-09-16 08:01:00, down 0.48% ($0.01) from the previous close of $1.05
Pre-market trading shows how investors are pricing INAB before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, IN8bio, Inc. (INAB) moved from $1.20 to $1.05, representing a decline of 12.92% ($0.16).
The stock traded between $1.01 and $1.22 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 31.27 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 8.9%
INAB is currently trading at $1.05, placing it 8.9% of the way from its 52-week low of $0.88 to its 52-week high of $2.73. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 18 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of IN8bio, Inc. (INAB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.